Balaji Amines Limited, a leading manufacturer of Aliphatic Amines & Speciality Chemicals in India, specialised in manufacturing of Methyl Amines, Ethyl Amines, Derivatives of Amines and other Specialty Chemicals, announced its audited financial results for the quarter and year ended March 31st, 2025.

During Q4 FY25, the company’s consolidated Revenue from Operations stood at Rs. 361 crore, as compared to Rs. 321 crore in Q3 FY25. Total volumes stood at 25,871 MT for Q4 FY25 as against 24,107 MT in Q3 FY25.

EBITDA for Q4 FY25 was Rs. 68 crore, as compared to Rs. 54 crore in Q3 FY25 and Rs. 106 crore in Q4 FY24. EBITDA margin for Q4 FY25 stood at 19 per cent as against 17 per cent in Q3 FY25 and 25 per cent in Q4 FY24.

PAT for Q4 FY25 was Rs. 40 crore as compared to Rs. 31 crore in Q3 FY25. Diluted EPS for Q4 FY25 stood at Rs. 12.36 per equity share as against Rs. 10.24 in Q3 FY25.

On a standalone basis, we are a zero-debt company.

Update on New Projects Commissioned and New Proposed Products/Projects

Solar Power plan: First phase of Solar power plant of 8 MW DC(6 MW AC) is commissioned in April 2025. This will reduce the power bills of all the plants substantially in line with our commitment of Carbon emission reduction under ESG declarations.

Electronic Grade Di Methyl Carbonate (DMC): Existing DMC plant is added with new Equipment for ELectronic Grade DMC. The plant was commissioned successfully on 28th May, 2025. The Propylene Glycol Pharma grade plant is likely to be commissioned in Q1 FY 25-26.

Di Methyl Ether: The plant is under construction and likely to be commissioned in this Financial Year 2025-26.

N-Methyl Morpholine(NMM): The NMM plant with a capacity of 15 MT/Day is under execution at Unit IV. Most of the equipment is ordered. The civil works are in progress. The plant is likely to be commissioned during the Financial Year 2025-26.

Iso Propyl Amine: The company has modified the existing Ethyl Amines plant at Unit-I suitable to manufacture Iso Propyl Amines (MIPA/DIPA). The capacity of the plant will be around 20 to 21 Tons per day. Most of the existing equipment of the Ethyl Amines plant is being used. The plant is likely to be commissioned after receipt of Consent for Operations from MPCB.

The company has taken up a project for upgradation of technology and increasing the capacity of existing ACN plant to a capacity of 60 MT/Day at Unit-III MIDC, Chincholi. The detailed engineering and ordering of critical and long delivery equipment are in progress and the plant is expected to be commissioned during the FY 2026-27.

New Projects

The company is proposing to set up a plant for manufacture of N-(N-Butyl) Thiophosphoric Triamide(NBPT) with a capacity of 2500 TPA which will be taken up next Financial Year.

All the above projects are likely to be completed by using internal accruals.

New expansion of approx. Rs. 750 crore in Subsidiary Balaji Speciality Chemicals Limited.

The Greenfield project for manufacture of Hydrogen Cyanide (HCN), Sodium Cyanide (NaCN) 30%(Solution), Sodium Cyanide (NaCN) 100%(Solid), Ethylene Diamine Tetra Acetic Acid (EDTA)/(EDTA-2Na), Benzyl Cyanide (BnCN), Phenylacetic Acid (PAA), and Tri Ethyl Ortho Formate (TEOF)/Tri Methyl Ortho Formate (TMOF) is under execution and is expected to be commissioned during the end of the FY 2025-26.

Further, the brownfield project for manufacture of EDA based products in the Unit - I is progressing as planned and the same is expected to be commissioned in the FY 2026-27.

On the performance, D. Ram Reddy, Managing Director, commented, “During Q4 FY25, our business performance showed improvement compared to the rest of the financial year, supported by favorable global macroeconomic conditions. As volume uptake gradually increases, we expect EBITDA and PAT margins to improve in line with broader industry recovery trends. However, geopolitical tensions and tariff-related challenges across global markets may continue to impact growth across several sectors in which we operate. These factors have weighed on domestic demand, but we anticipate that better utilization of expanded capacities will support margin recovery in the coming quarters.

Pharmaceutical sector demand remained steady, contributing to base volumes, while the agrochemical segment exhibited volatility during the quarter. We continue to make progress on our strategic capex initiatives, including Electronic Grade DMC, Propylene Glycol Pharma Grade, and Dimethyl Ether projects, which are moving forward as planned.

On the sustainability front, we are pleased to announce that our 6 MW AC Solar Power Plant was commissioned on 2nd April, 2025. The plant is being brought online in a phased manner under Grid Connectivity, and the power generated will be utilized for captive consumption. Looking ahead, we remain focused on enhancing operational efficiencies, managing input costs and expanding our product portfolio to deliver sustained value to all stakeholders.”